Venus Remedies Ltd
Incorporated in 1989, Venus Remedies
Ltd is a research based pharmaceutical company and an injectable manufacturer[1]
- Market Cap ₹ 398 Cr.
- Current Price ₹ 299
- High / Low ₹ 430 / 280
- Stock P/E 18.0
- Book Value ₹ 370
- Dividend Yield 0.00 %
- ROCE 8.57 %
- ROE 5.94 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.81 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 7.13% over last 3 years.
- Earnings include an other income of Rs.18.4 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
459 | 531 | 455 | 407 | 400 | 372 | 322 | 335 | 544 | 597 | 552 | 596 | 615 | |
339 | 393 | 366 | 326 | 349 | 333 | 289 | 295 | 490 | 535 | 492 | 537 | 567 | |
Operating Profit | 120 | 138 | 89 | 81 | 51 | 39 | 33 | 41 | 54 | 62 | 60 | 60 | 48 |
OPM % | 26% | 26% | 20% | 20% | 13% | 11% | 10% | 12% | 10% | 10% | 11% | 10% | 8% |
0 | 0 | 1 | 2 | 2 | 2 | -3 | -4 | 43 | 8 | 10 | 12 | 18 | |
Interest | 25 | 29 | 41 | 38 | 34 | 35 | 25 | 13 | 13 | 0 | 0 | 0 | 0 |
Depreciation | 33 | 40 | 46 | 42 | 40 | 34 | 34 | 32 | 35 | 34 | 32 | 26 | 25 |
Profit before tax | 63 | 69 | 3 | 4 | -22 | -28 | -30 | -8 | 49 | 36 | 38 | 45 | 41 |
Tax % | 9% | 7% | -95% | 52% | -21% | 11% | -4% | 24% | -27% | -12% | 30% | 36% | |
57 | 64 | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 41 | 27 | 28 | 22 | |
EPS in Rs | 54.36 | 56.20 | 4.51 | 1.49 | -13.84 | -24.87 | -23.15 | -8.10 | 50.05 | 30.46 | 19.88 | 21.31 | 16.52 |
Dividend Payout % | 6% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 1% |
5 Years: | 13% |
3 Years: | 3% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | -8% |
5 Years: | 28% |
3 Years: | -10% |
TTM: | -13% |
Stock Price CAGR | |
---|---|
10 Years: | 3% |
5 Years: | 68% |
3 Years: | -10% |
1 Year: | -19% |
Return on Equity | |
---|---|
10 Years: | 2% |
5 Years: | 6% |
3 Years: | 7% |
Last Year: | 6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 13 |
Reserves | 364 | 450 | 445 | 426 | 376 | 350 | 320 | 311 | 374 | 427 | 447 | 474 | 481 |
271 | 289 | 321 | 335 | 312 | 307 | 298 | 220 | 51 | 43 | 42 | 41 | 41 | |
72 | 84 | 64 | 70 | 65 | 82 | 102 | 100 | 118 | 97 | 98 | 98 | 125 | |
Total Liabilities | 718 | 834 | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 660 |
401 | 439 | 444 | 452 | 406 | 389 | 364 | 289 | 262 | 241 | 216 | 219 | 237 | |
CWIP | 48 | 68 | 78 | 80 | 66 | 65 | 65 | 25 | 25 | 25 | 26 | 21 | 23 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 19 | 56 |
268 | 327 | 319 | 310 | 293 | 297 | 304 | 330 | 269 | 314 | 339 | 368 | 345 | |
Total Assets | 718 | 834 | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 660 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
52 | 53 | 68 | 47 | 59 | 31 | 45 | 78 | 132 | 41 | 37 | 37 | |
-104 | -95 | -67 | 3 | -18 | 8 | -11 | -5 | 57 | -17 | -58 | -8 | |
55 | 40 | -1 | -46 | -44 | -39 | -35 | -73 | -162 | -9 | -1 | -1 | |
Net Cash Flow | 3 | -2 | -1 | 3 | -4 | 0 | -1 | -0 | 27 | 14 | -22 | 28 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 37 | 45 | 51 | 55 | 43 | 46 | 43 | 33 | 21 | 24 | 51 | 49 |
Inventory Days | 178 | 173 | 194 | 219 | 226 | 246 | 286 | 296 | 129 | 118 | 132 | 125 |
Days Payable | 26 | 38 | 40 | 38 | 48 | 52 | 72 | 77 | 76 | 47 | 56 | 45 |
Cash Conversion Cycle | 190 | 180 | 204 | 236 | 221 | 240 | 257 | 252 | 74 | 95 | 127 | 129 |
Working Capital Days | 98 | 115 | 146 | 179 | 163 | 144 | 127 | 166 | 74 | 85 | 112 | 120 |
ROCE % | 15% | 14% | 6% | 5% | 2% | 1% | 1% | 2% | 8% | 8% | 8% | 9% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
5 Nov - Venus Remedies receives GMP approval for pre-filled syringe facility.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 Oct - Newspaper publication for UFR as on 30th Sep 2024.
-
Board Meeting Outcome for Outcome Of Board Meeting Dated 29.10.24
29 Oct - Approved standalone and consolidated financial results for Q2 2024.
- Financial Results As On 30.09.2024 29 Oct
-
Board Meeting Intimation for Boar Meeting Is Scheduled For 29Th October 2024.
18 Oct - Notice of Board Meeting on October 29, 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
VSR is one of the largest manufacturers of meropenem antibiotics and emerging player in AMR drug in India. It offers a wide range of pharmaceutical products that cater to various therapeutic areas, including anti infective (antibiotics), antimicrobial resistance, oncology, neurology, pain management, skin
& wound care. Company has 1040+ marketing authorizations globally, 135+ patents and 180+ product basket which includes formulations such as injectables,
tablets, and topical preparations